Please make a donation to the Aplastic Anemia and MDS International Foundation.
Donate Today
In January 2025, life felt full of momentum. My husband and I had just moved from Colorado to Tennessee to be closer to family. I was beginning my real estate career, we had just bought our first house, and we had our two precious daughters, just 2 years and 10 months old.
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System (IPSS). We conducted a phase 2…
Abstract Health-related quality of life (HRQoL) of patients with myeloproliferative neoplasms (MPNs) may be impaired across several domains. In this multicenter observational study, we evaluated HRQoL and symptoms in a cohort of MPN patients with validated measures, including the…
ABSTRACT The COMMANDS trial established luspatercept as a first-line treatment for anemia in transfusion-dependent lower-risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease…
Patients with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood c
In November 2016, at just 36 years old, Greg was diagnosed with severe aplastic anemia aplastic anemia:
Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile. Treatment with the hepcidin mimetic rusfertide continued to demonstrate sustained hematocrit control below 45% and high…
